What is Retatrutide?

Retatrutide (research code LY3437943) is a synthetic peptide studied as a triple agonist — it acts on the GLP-1, GIP, and glucagon receptors at once. That third receptor is the difference between Retatrutide and the dual-agonist peptides researchers are more familiar with.

It is supplied as a lyophilised (freeze-dried) powder in a sealed glass vial. The powder is stable, light, and shipped without a cold chain in most cases; it becomes a solution only once a researcher reconstitutes it with bacteriostatic water.

Because all three pathways are engaged, published research protocols escalate dosing slowly rather than starting at a maintenance level. That is why almost every reference protocol you will see begins in fractions of a milligram.

• Format: lyophilised white powder in a sealed, stoppered glass vial.
• Strength: Origen supplies 30 mg per vial — larger than the 10 mg and 20 mg vials commonly sold, so one vial covers a longer research cycle.
• Reconstitution: typically 3 mL of bacteriostatic water, giving 10 mg/mL.
• Documentation: an independent Janoshik Analytical certificate covering purity, quantity, and endotoxin.

1. 1A third-party COA that names the analysing lab — not a screenshot or a generic 'lab tested' badge.
2. 2Purity reported by HPLC, with the chromatogram included rather than a single number.
3. 3Endotoxin results, not just purity.
4. 4A certificate that matches the exact product you are being sold, published before the product goes on sale.

Every Origen product page links directly to its published certificate, and you can search the full library by product name from the certificate lookup.